February 06, 2018
1 min read

Allergan reports 12% increase in fourth quarter revenues

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Allergan reported $4.3 billion in fourth quarter GAAP net revenues, a 12% increase over the previous year’s fourth quarter, according to a company press release. Full-year net revenues increased to $15.9 billion.

GAAP operating loss from continuing operations was $90.5 million in the fourth quarter and $5.9 billion for the year, which the company attributed to impairment charges and research and development costs.

Revenues for the eye care arm increased to $671.7 million in 2017’s fourth quarter compared with $660.1 million in 2016’s fourth quarter. Restasis net revenues increased 1.8% to $400.3 million, while revenues for Ozurdex went up 16.8% to $26.4 million. Glaucoma products had a slight decline in revenue, with Alphagan/Combigan remaining stable at $101.8 million and Lumigan/Ganfort revenues decreasing 5.9% to $80.9 million.

For 2017, eye care revenues increased 0.9% to $2.46 billion.

Revenues for the facial aesthetics group increased 14.1% in the fourth quarter, with Botox revenues increasing 14.5% to $228.4 million. For the full year, facial aesthetics revenues increased 11.1% to $1.36 billion.